00455 TIANDA PHARMA
- 0.265
- +0.010+3.92%
TIANDA PHARMA News
天大藥業：2023年報
TIANDA PHARMA To Go Ex-Dividend On June 13th, 2024 With 0.0026 HKD Dividend Per Share
April 10th - $TIANDA PHARMA(00455.HK)$ is trading ex-dividend on June 13th, 2024. Shareholders of record on June 14th, 2024 will receive 0.0026 HKD dividend per share on June 28th, 2024. The ex-di
Tianda Pharmaceutical (00455) will pay a final dividend of HK0.26 cents per share on June 28
Tianda Pharmaceutical (00455) announced that it intends to make final payments for the year ended December 31, 2023...
TIANDA PHARMA: FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2023 CLOSURES OF REGISTER OF MEMBERS
Tianda Pharmaceutical (00455) announced annual results. The loss attributable to shareholders of HK$24.155 million decreased by 41.05% year-on-year
According to the Zhitong Finance App, Tianda Pharmaceutical (00455) announced its annual results for the year ended December 31, 2023. The group obtained revenue of HK$532 million, an increase of 29.77% year on year; loss due to shareholders of the parent company was HK$24.155 million, a decrease of 41.05% year on year; loss per share was 1.12 HK cents, and a final dividend of HK 0.26 cents per share was planned. In the pharmaceutical and medical technology business, benefiting from strong sales growth of the pediatric drug tonibuprofen and the maintenance of ideal sales performance for other major products, this year's revenue was HK$470.7 million (previous financial period: 3.45)
Tianda Pharmaceutical (00455) plans to pay a final dividend of HK$0.0026 per share
Tianda Pharmaceutical (00455) announced that it intends to distribute final shares for the year ended December 31, 2023...
TIANDA PHARMA: FINAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Tianda Pharmaceutical (00455) expects losses in 2023 to be reduced by more than HK$15 million compared to the previous period
Tianda Pharmaceutical (00455) announced that the company's fiscal year settlement date has been changed from March 31 to December 3...
Tianda Pharmaceutical (00455.HK) plans to hold a board meeting on March 26 to approve the annual results
Gelonghui March 14 | Tianda Pharmaceutical (00455.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
CITIC Construction Investment: Positive year-on-year growth in pharmaceutical revenue in the first three quarters favors prescription drugs, traditional Chinese medicine, etc.
The overall sector's revenue in the first three quarters of 2023 achieved positive year-on-year growth, and the growth rate declined in the third quarter. The growth rate slowed mainly due to increased compliance requirements, but the downturn was not overshadowed, and immediate demand and innovation drove the industry's Q3 revenue to continue to grow.
Analysis
Price Target
No Data
